Summary Cyclic AMP Binding Proteins (cAMP-BP) levels have been measured by means of a competitive binding assay in the cytosols of 50 human colorectal cancers. These levels have been related to those in mucosa both adjacent to and distant from the tumour in the same patients. Cyclic AMP-BP were higher in tumour than in either adjacent (P<0.000001) or distant mucosa (P<0.00001). Binding of cAMP in adjacent mucosa was lower than that in distant mucosa (P<0.0001). There was no significant difference in the level of binding between tumours arising from different sites in the colon and binding was not related to age or sex of the patient. However, binding was higher in Dukes' B than Dukes' C cancers (P<0.005). There was also a trend for cAMP binding levels to be higher in moderately differentiated than in poorly differentiated cancers (P = 0.07). Thus cAMP-BP appear to be over-expressed in human colorectal cancers and levels are related to the stage and grade.
Cyclic adenosine 3',5'-monophosphate (cAMP) functions as a secondary messenger for a wide range of hormones releasing factors and drugs. The cAMP signalling system also interacts with other signalling pathways that are used by locally-acting growth factors (Olashaw & Pledger, 1988) to bring about co-ordinated control of basic cell processes such as proliferation and differentiation. Cyclic AMP exerts all its known effects through binding to and activating a specific cAMPdependent protein kinase, also known as Protein Kinase A (PK-A) (Taylor et al., 1989) . PK-A is a tetrameric holoenzyme comprising two regulatory units (R) , and two catalytic units (C). R units, also known as cAMP binding proteins (cAMP-BP) act as pseudosubstrate for the C units and so prevent them from carrying out phosphorylation within the cell (Shenolikar, 1988) . Activation of PK-A follows binding of cAMP to R units and their dissociation from the C unit. As well as leading to protein phosphorylation, activation PK-A also brings about changes in expression of cAMP dependent genes, although the exact mechanisms are, as yet, unclear (Roesler et al., 1988) . Conventionally, cAMP has been considered a negative signal to cellular proliferation although stimulatory effects have been described depending on the cell type, phase in the cell cycle and presence of other growth factors (Dumont et al., 1989) . Cyclic AMP analogues have been shown to inhibit the growth and promote the differentiation of a number of human cancer cell lines in vitro including those derived from colorectal cancer (Ally et al., 1988) . In animal studies the production of colonic tumours by chemical carcinogens has been associated with decreased levels of PK-A activity (DeRubertis & Craven, 1980) . Furthermore, cAMP and cAMP-dependent protein kinase levels have been reported to be lower in human colorectal cancers and villous adenomas than in normal mucosa (Alexandrov et al., 1986) . By contrast, in breast cancer cAMP-BP levels are of independent prognostic significance (Miller et al., 1990) with higher levels of binding being associated with reduced disease free interval and decreased survival. The aim of this study was to determine the levels of cAMP-BP in human colorectal cancers and related mucosa and to correlate these levels to known prognostic factors; namely stage and grade. (Bradford, 1976) . Bovine serum albumen (Sigma) was used as a standard.
Methods
Cyclic AMP binding assay The cytosol (50 gl) was incubated in duplicate overnight at 4°C with 100yl1 of 25 nm (to give a final concentration of 10 nM) 5'8-3H-cAMP (Sp. Ac. 44.5-59 Ci mmol-' Amersham International) and 100 gl of assay buffer (55 mm potassium phosphate with the fresh addition of 11 mM theophylline) containing increasing final concentrations (0, 10, 20, 40, 80 , 10,000 nM) or radio-inert cAMP (Sigma). Bound and free cAMP were then separated by filtration (Millipore HAWP 0.45 gm). Filters were washed in assay buffer containing 10 mM magnesium chloride and allowed to dry. Scintillant (5 ml, NE-260 Nuclear Enterprises) was added to each vial and incubated for 2 h at 37°C. The vials were then counted in (Prashad, 1982) . This study also demonstrates that levels of cAMP binding in mucosa immediately adjacent to the tumours is lower than that in distant mucosa. Thus there appears to be a zone of depressed binding surrounding the tumour. It is possible that the tumour is releasing some, as yet unidentified, locally acting factor that is suppressing the surrounding mucosa. In this respect it has been shown that colorectal cancers are capable of secreting biologically active factors; for example Pommier (1988) has demonstrated the release of an autocrine growth factor by colorectal cancer cell lines. Alternatively, a 'transitional' mucosa surrounding colorectal cancers has been described characterised by inflammatory cell infiltrate, goblet and basal cell hyperplasia, mucosal ulceration and ischaemia (Lee, 1988 (Miller et al., 1990) . Despite stage and grade being general indicators of overall prognosis in colorectal cancer (Wiggers et al., 1988) , they are of limited use in predicting outcome for individual patients (Fielding et al., 1986) (Lipkin, 1988) . Furthermore, increases in pan-colonic proliferative indices have been linked to the presence and size of colonic adenomas and cancers (Terpstra et al., 1987) . Lower levels PK-A activity have been reported in the proliferative compartment of colonic crypts (Schwartz et al., 1988) and it may be that levels of cAMP binding found in this study reflect overall proliferative changes.
Because of the very significant differences in the level of expression of cAMP binding proteins between benign and malignant tissue in this study, it is relevant to discuss briefly the biology of cAMP binding proteins as it might relate to the malignant process. In addition to their role in regulating the kinase activity of PK-A, it has been postulated that cAMP binding proteins might have independent function in the regulation of cAMP gene transcription (Zwelling, 1988 been possible to separate cAMP binding proteins from Topoisomerase activity (Shabb & Granner, 1988 , Hunzicker-Dunn et al., 1989 . Despite these conflicting findings, cAMP binding proteins have been shown to enter the nucleus following PK-A activation (Tagliaferri et al., 1988) and to associate with transcriptionally active chromatin during changes in gene expression (Sikorska et al., 1988) . Furthermore, cAMP has been shown to enhance the ability of cAMP binding proteins to bind oligonucleotide in a sequence-selective manner (Wu & Wang, 1989) . Thus although many of the changes in cAMP dependent gene expression are due to the phosphorylation and activation of transcription factors by the catalytic subunit of PK-A (Ziff, 1990) there is increasing evidence that the regulatory cAMP binding subunits play an independent or modulating role. Interestingly, the ability of cAMP analogs to reverse the malignant phenotype of a number of cell lines including those derived from human colorectal cancer is associated with changes in the expression of cAMP binding proteins and the movement of binding proteins in to the nucleus (Cho-Chung et al., 1989) . Cyclic AMP binding proteins may therefore have an important role in controlling the expression of genes involved in development of the malignant state. Irrespective of their mechanism of action, the results presented in this paper clearly demonstrate that an abnormality within the cAMP signalling system is associated with the development and possibly the progression of human colorectal cancers. This is the first report of such a finding and indicates that a defect in cellular control normally exerted through the cAMP system may be involved in colorectal carcinogenesis.
